“The Uveal Melanoma market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple- Uveal Melanoma pipeline products will significantly revolutionize the Uveal Melanoma market dynamics”
The Uveal Melanoma market report provides current treatment practices, emerging drugs, Uveal Melanoma market share of the individual therapies, current and forecasted Uveal Melanoma market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current Uveal Melanoma treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Uveal Melanoma market.
Key Takeaways from the Uveal Melanoma Market Report
- The Uveal Melanoma market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
- As per Ahmad et al. (2021), the overall age-standardized incidence rate (ASIR) of uveal melanoma in Germany was 6.41 person per million.
- The leading Uveal Melanoma Companies include Delcath System, Aura Biosciences, Seagen, IDEAYA, Linnaeus Therapeutics, Ascentage Pharma, AstraZeneca, IQVIA Biotech and others.
- Promising Uveal Melanoma Pipeline Therapies include Melphalan, AU-011 (bezupacap sarotalocan), SEA-CD40, IDE 196 (darovasertib), LNS8801, APG-115, Dacarbazine and others.
Discover more about therapies set to grab major Uveal Melanoma market share @ Uveal Melanoma Market Size
Uveal Melanoma Overview
Uveal melanoma is the most common primary intraocular malignancy in adults. Intraocular is a disease in which malignant cells form in the tissues of the eye. Signs of intraocular melanoma include blurred vision or a dark spot on the iris.
Uveal Melanoma Epidemiology Segmentation in the 7MM
- Total Uveal melanoma Incident Cases
- Uveal melanoma Site-Specific Cases
- Uveal melanoma Mutation-Specific Cases
- Uveal melanoma Stage-specific Cases
- Total Uveal melanoma Treated Cases
Download the report to understand which factors are driving Uveal Melanoma epidemiology trends @ Uveal Melanoma Epidemiological Insights
Recent Developmental Activities in the Uveal Melanoma Treatment Landscape
- Delcath Systems’ Melphalan is being developed in patients for the treatment of Patients with Unresectable Hepatic-Dominant Ocular Melanoma. Melphalan is a bifunctional alkylating agent, active against both resting and rapidly dividing tumor cells.
- Aura Biosciences is developing a pipeline of virus-like drug conjugate, or VDC, therapeutic candidates for high unmet need cancers that either have no approved drugs available or are poorly managed with currently available treatments. The company’s first VDC, AU-011 (belzupacap sarotalocan) has recently completed Phase II clinical trial for the first line treatment of primary choroidal melanoma. AU-011 is a first-in-class targeted therapy which consists of viral nanoparticle conjugates that bind selectively to cancer cells in the eye. Upon activation with an ophthalmic laser, the drug rapidly and specifically destroys the membranes of tumor cells while sparing key eye structures, which may allow for the potential of preserving patients’ vision. AU-011 for ocular melanoma has been granted orphan drug and fast track designations by the US FDA.
- SEA-CD40 is Seagen’s novel, investigational, nonfucosylated monoclonal receptor-agonistic antibody directed to CD40, which is expressed on antigen-presenting cells. The drug utilizes the company’s Sugar-Engineered Antibody (SEA) Technology. SEA technology therapies that can empower antibodies to directly stimulate the immune system to destroy tumors. SEA technology is a method to selectively reduce fucose incorporation in monoclonal antibodies as they are produced in cell line-based manufacturing. By growing antibody-producing cells in the presence of the 2-fluorofucose sugar, the cellular fucosylation pathway is blocked. This creates afucosylated antibodies that can bind more tightly to an activating receptor on innate immune cells increasing receptor cross-linking and improving antibody-dependent cellular cytotoxicity, an important antitumor immune response.
Uveal Melanoma Treatment Market
Treatment for uveal melanoma largely depends on the stage of the cancer and the location. The most common types of treatment include Surgery (Resection, Enucleation, Exenteration), Radiation Therapy ((External radiation:-Charged-particle external beam radiation therapy and Gamma Knife therapy) and Internal radiation :- Localized plaque radiation therapy), Photocoagulation, Thermotherapy. The main goals of ocular melanoma treatment are to destroy the tumor, prevent recurrence and metastasis, and conserve vision. The treatment of primary uveal melanoma has constantly improved over time and different irradiation procedures have successfully replaced enucleation in selected cases. There are different types of treatments which are currently being used for the treatment of Uveal Melanoma which includes Surgery, Radiation therapy, Photocoagulation, Thermotherapy.
To know more about Uveal Melanoma Treatment options, visit @ Uveal Melanoma Drugs
Uveal Melanoma Market Dynamics
The dynamics of Uveal Melanoma market is anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, rising awareness of the diseases, incremental healthcare spending across the world and expected launch of emerging therapies during the forecast period of 2022–2032. Companies across the globe are working towards the development of new treatment therapies for mantle cell lymphoma.
Uveal Melanoma Companies
- Delcath System
- Aura Biosciences
- Seagen
- IDEAYA
- Linnaeus Therapeutics
- Ascentage Pharma
- AstraZeneca
- IQVIA Biotech, and others
Uveal Melanoma Pipeline Therapies
- Melphalan
- AU-011 (bezupacap sarotalocan)
- SEA-CD40
- IDE 196 (darovasertib)
- LNS8801
- APG-115
- Dacarbazine, and others
Learn more about the Uveal Melanoma Pipeline Therapies in clinical trials @ New Treatment for Uveal Melanoma
Scope of the Uveal Melanoma Market Report
- Coverage- 7MM
- Uveal Melanoma Companies- Delcath System (NYSE: DCTH), Aura Biosciences (NYSE: AURA), Seagen (NYSE: SGEN), IDEAYA (NYSE: IDYA), Linnaeus Therapeutics, Ascentage Pharma (NYSE: ASPHF), AstraZeneca (NYSE: AZN), IQVIA Biotech (NYSE: IQV) and others.
- Uveal Melanoma Pipeline Therapies- Melphalan, AU-011 (bezupacap sarotalocan), SEA-CD40, IDE 196 (darovasertib), LNS8801, APG-115, Dacarbazine and others
- Uveal Melanoma Market Dynamics: Uveal Melanoma Market Drivers and Barriers
- Uveal Melanoma Market Access and Reimbursement
Discover more about Uveal Melanoma Drugs in development @ Uveal Melanoma Ongoing Clinical Trials Analysis
Table of Content
- Key Insights
- Executive Summary of Uveal Melanoma
- Competitive Intelligence Analysis for Uveal Melanoma
- Uveal Melanoma: Market Overview at a Glance
- Uveal Melanoma: Disease Background and Overview
- Patient Journey
- Uveal Melanoma Epidemiology and Patient Population
- Treatment Algorithm, Current Treatment, and Medical Practices
- Uveal Melanoma Unmet Needs
- Key Endpoints of Uveal Melanoma Treatment
- Uveal Melanoma Marketed Products
- Uveal Melanoma Emerging Therapies
- Uveal Melanoma: Seven Major Market Analysis
- Attribute analysis
- 7MM: Uveal Melanoma Market Outlook
- Uveal Melanoma Market Access and Reimbursement Overview
- KOL Views
- Uveal Melanoma Market Drivers
- Uveal Melanoma Market Barriers
- Appendix
- DelveInsight Capabilities
- Disclaimer
- About DelveInsight
Get in touch with our Business executive @ Uveal Melanoma Market Drivers and Barriers
Top Selling Market Research Reports in 2023
AIDS Related Kaposi’s Sarcoma Market |AL Amyloidosis Market | Abdominal Aortic Aneurysm Market | X-Linked Retinitis Pigmentosa Market | Wiskott-aldrich Syndrome Market | Urology Ultrasounds Devices Market | Uncomplicated Urinary Tract Infection Market | Tropical Spastic Paraparesis Market | Systemic Sclerosis-associated Interstitial Lung Disease Market | Spondylolisthesis Market
Trending Report
Concussions Market Size | Pruritus Market | Angioedema Market | Blood Gas And Electrolyte Analyzers Market | Human Papilomavirus Market | Neurovascular Devices Market | Pain Management Devices Market | Pressure Ulcers Market Size | Acute Coronary Syndrome Market | Apheresis Market | Arteriotomy Closure Devices Market | Automated External Defibrillators Market | Xerostomia Market | Choroidal Neovascularization Market | Hyperhidrosis Market | Alopecia Market | Contraceptive Devices Market | Ventilator Market | Alopecia Aerata Market | Osteoarthritis Market | Neurostimulation Devices Market | Global Electrophysiology Devices Market | Astigmatism Market | Graves Orbitopathy Market | HPV-Induced Cancers Market | Hypothalamic Obesity Market | Italy healthcare outlook report
Consulting Services:
Biotech Consulting | Business Consulting Services | Consulting Services | Healthcare Business Development | Healthcare Consulting Services | Healthcare Strategy Consulting | Life Science Consulting | Life Science Consulting Firms
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Healthcare Market Research Reports, Competitive Landscaping, and Mergers & Acquisitions.
Contact Us
Yash Bhardwaj
info@delveinsight.com